Phase Bioscience Announces Collaboration with Centocor Research and Development
News Jan 07, 2008
PhaseBio’s deltaPhase technology offers new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods.
According to PhaseBio, the advantages seen with its process include: increased yields, high throughput and elimination of chromatography steps for final product purification. “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio,” stated Clay B. Thorp, Chairman of the Board, Phase Bioscience, Inc.
Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research.
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019